Mawer Investment Management Ltd. raised its holdings in Danaher Co. (NYSE:DHR) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 196,844 shares of the conglomerate’s stock after purchasing an additional 2,854 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Danaher were worth $43,727,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Hudock Inc. increased its stake in Danaher by 526.3% in the fourth quarter. Hudock Inc. now owns 119 shares of the conglomerate’s stock valued at $26,000 after purchasing an additional 100 shares during the period. Financial Avengers Inc. acquired a new position in Danaher in the fourth quarter valued at $40,000. Atlas Private Wealth Management acquired a new position in Danaher in the third quarter valued at $41,000. Oakworth Capital Inc. increased its stake in Danaher by 48.9% in the third quarter. Oakworth Capital Inc. now owns 198 shares of the conglomerate’s stock valued at $43,000 after purchasing an additional 65 shares during the period. Finally, University of Texas Texas AM Investment Managment Co. acquired a new position in Danaher in the third quarter valued at $53,000. Institutional investors own 78.00% of the company’s stock.
In other Danaher news, SVP Angela S. Lalor sold 6,437 shares of Danaher stock in a transaction dated Friday, February 12th. The shares were sold at an average price of $244.70, for a total transaction of $1,575,133.90. Following the completion of the transaction, the senior vice president now owns 25,148 shares in the company, valued at $6,153,715.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 11.70% of the company’s stock.
Danaher (NYSE:DHR) last announced its earnings results on Thursday, January 28th. The conglomerate reported $2.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.24. The company had revenue of $6.76 billion during the quarter, compared to analysts’ expectations of $6.62 billion. Danaher had a net margin of 18.05% and a return on equity of 12.94%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.28 earnings per share. As a group, analysts expect that Danaher Co. will post 6.05 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, January 29th. Shareholders of record on Monday, December 28th were given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date was Thursday, December 24th. Danaher’s payout ratio is currently 16.29%.
DHR has been the topic of several analyst reports. KeyCorp initiated coverage on shares of Danaher in a report on Monday, November 9th. They issued an “overweight” rating and a $280.00 target price on the stock. Credit Suisse Group lifted their target price on shares of Danaher from $260.00 to $264.00 and gave the company an “outperform” rating in a report on Thursday, January 14th. The Goldman Sachs Group initiated coverage on shares of Danaher in a report on Wednesday, December 2nd. They issued a “buy” rating and a $250.00 target price on the stock. Royal Bank of Canada downgraded shares of Danaher from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $273.00 to $234.00 in a report on Wednesday, November 25th. Finally, Needham & Company LLC lifted their target price on shares of Danaher from $209.00 to $272.00 in a report on Tuesday, October 27th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Danaher presently has an average rating of “Buy” and a consensus target price of $233.00.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.